TY - JOUR
T1 - Challenges and recommendations for the translation of biomarkers of aging
AU - Herzog, Chiara M.S.
AU - Goeminne, Ludger J.E.
AU - Poganik, Jesse R.
AU - Barzilai, Nir
AU - Belsky, Daniel W.
AU - Betts-LaCroix, Joe
AU - Chen, Brian H.
AU - Chen, Michelle
AU - Cohen, Alan A.
AU - Cummings, Steven R.
AU - Fedichev, Peter O.
AU - Ferrucci, Luigi
AU - Fleming, Alexander
AU - Fortney, Kristen
AU - Furman, David
AU - Gorbunova, Vera
AU - Higgins-Chen, Albert
AU - Hood, Lee
AU - Horvath, Steve
AU - Justice, Jamie N.
AU - Kiel, Douglas P.
AU - Kuchel, George A.
AU - Lasky-Su, Jessica
AU - LeBrasseur, Nathan K.
AU - Maier, Andrea B.
AU - Schilling, Birgit
AU - Sebastiano, Vittorio
AU - Slagboom, P. Eline
AU - Snyder, Michael P.
AU - Verdin, Eric
AU - Widschwendter, Martin
AU - Zhavoronkov, Alex
AU - Moqri, Mahdi
AU - Gladyshev, Vadim N.
AU - Biomarkers of Aging Consortium
N1 - Publisher Copyright:
© Springer Nature America, Inc. 2024.
PY - 2024/10
Y1 - 2024/10
N2 - Biomarkers of aging (BOA) are quantitative parameters that predict biological age and ideally its changes in response to interventions. In recent years, many promising molecular and omic BOA have emerged with an enormous potential for translational geroscience and improving healthspan. However, clinical translation remains limited, in part due to the gap between preclinical research and the application of BOA in clinical research and other translational settings. We surveyed experts in these areas to better understand current challenges for the translation of aging biomarkers. We identified six key barriers to clinical translation and developed guidance for the field to overcome them. Core recommendations include linking BOA to clinically actionable insights, improving affordability and availability to broad populations and validation of biomarkers that are robust and responsive at the level of individuals. Our work provides key insights and practical recommendations to overcome barriers impeding clinical translation of BOA.
AB - Biomarkers of aging (BOA) are quantitative parameters that predict biological age and ideally its changes in response to interventions. In recent years, many promising molecular and omic BOA have emerged with an enormous potential for translational geroscience and improving healthspan. However, clinical translation remains limited, in part due to the gap between preclinical research and the application of BOA in clinical research and other translational settings. We surveyed experts in these areas to better understand current challenges for the translation of aging biomarkers. We identified six key barriers to clinical translation and developed guidance for the field to overcome them. Core recommendations include linking BOA to clinically actionable insights, improving affordability and availability to broad populations and validation of biomarkers that are robust and responsive at the level of individuals. Our work provides key insights and practical recommendations to overcome barriers impeding clinical translation of BOA.
UR - https://www.scopus.com/pages/publications/85204244453
UR - https://www.scopus.com/inward/citedby.url?scp=85204244453&partnerID=8YFLogxK
U2 - 10.1038/s43587-024-00683-3
DO - 10.1038/s43587-024-00683-3
M3 - Article
AN - SCOPUS:85204244453
SN - 2662-8465
VL - 4
SP - 1372
EP - 1383
JO - Nature Aging
JF - Nature Aging
IS - 10
ER -